ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
- First Posted Date
- 2010-08-05
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT01176266
- Locations
- 🇫🇷
Chu de Toulouse, Toulouse, France
🇷🇺Federal State Budgetary Institution, Moscow, Russian Federation
🇩🇪Universitätskinderklinikum Würzburg, Würzburg, Germany
Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)
- First Posted Date
- 2010-07-15
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT01163149
- Locations
- 🇨🇦
Health Sciences Centre Winnipeg, University of Manitoba, Winnipeg, Manitoba, Canada
🇺🇸Shriner's Hospital for Children, Saint Louis, Missouri, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT00952484
- Locations
- 🇺🇸
Shriners Hospital for Children, Saint Louis, Missouri, United States
🇨🇦The University of Manitoba Health Services Centre, Winnipeg, Manitoba, Canada
Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)
Phase 2
Withdrawn
- Conditions
- First Posted Date
- 2009-05-06
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT00894075
Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)
- First Posted Date
- 2009-03-24
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT00867932
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00844545
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT00844844
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT00844428
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00838513
Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT00744042
- Locations
- 🇺🇸
Vanderbilt Children's Hospital, Nashville, Tennessee, United States
🇺🇸Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸St. John's Hospital, Springfield, Missouri, United States
© Copyright 2024. All Rights Reserved by MedPath